Intrinsic value of Arrowhead Pharmaceuticals - ARWR

Previous Close

$12.98

  Intrinsic Value

$0.17

stock screener

  Rating & Target

str. sell

-99%

Previous close

$12.98

 
Intrinsic value

$0.17

 
Up/down potential

-99%

 
Rating

str. sell

We calculate the intrinsic value of ARWR stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  32
  33
  34
  35
  36
  37
  38
  39
  41
  42
  44
  46
  48
  50
  52
  54
  57
  59
  62
  65
  68
  71
  74
  78
  81
  85
  89
  94
  98
  103
Variable operating expenses, $m
  17,757
  18,165
  18,632
  19,156
  19,737
  20,374
  21,068
  21,819
  22,628
  23,496
  24,423
  25,415
  26,470
  27,592
  28,782
  30,043
  31,378
  32,790
  34,282
  35,857
  37,519
  39,272
  41,120
  43,066
  45,117
  47,275
  49,548
  51,938
  54,454
  57,100
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  17,757
  18,165
  18,632
  19,156
  19,737
  20,374
  21,068
  21,819
  22,628
  23,496
  24,423
  25,415
  26,470
  27,592
  28,782
  30,043
  31,378
  32,790
  34,282
  35,857
  37,519
  39,272
  41,120
  43,066
  45,117
  47,275
  49,548
  51,938
  54,454
  57,100
Operating income, $m
  -17,725
  -18,133
  -18,599
  -19,122
  -19,701
  -20,337
  -21,030
  -21,780
  -22,587
  -23,454
  -24,379
  -25,369
  -26,422
  -27,542
  -28,730
  -29,989
  -31,322
  -32,731
  -34,220
  -35,793
  -37,452
  -39,201
  -41,046
  -42,989
  -45,035
  -47,190
  -49,458
  -51,845
  -54,356
  -56,997
EBITDA, $m
  -17,720
  -18,127
  -18,593
  -19,116
  -19,696
  -20,331
  -21,024
  -21,773
  -22,581
  -23,447
  -24,375
  -25,364
  -26,417
  -27,537
  -28,724
  -29,983
  -31,316
  -32,725
  -34,214
  -35,786
  -37,444
  -39,194
  -41,038
  -42,980
  -45,027
  -47,181
  -49,448
  -51,835
  -54,345
  -56,985
Interest expense (income), $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  3
  3
Earnings before tax, $m
  -17,725
  -18,133
  -18,599
  -19,122
  -19,702
  -20,338
  -21,030
  -21,780
  -22,588
  -23,455
  -24,380
  -25,369
  -26,423
  -27,543
  -28,731
  -29,990
  -31,323
  -32,732
  -34,222
  -35,794
  -37,453
  -39,203
  -41,047
  -42,991
  -45,037
  -47,192
  -49,460
  -51,847
  -54,358
  -56,999
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -17,725
  -18,133
  -18,599
  -19,122
  -19,702
  -20,338
  -21,030
  -21,780
  -22,588
  -23,455
  -24,380
  -25,369
  -26,423
  -27,543
  -28,731
  -29,990
  -31,323
  -32,732
  -34,222
  -35,794
  -37,453
  -39,203
  -41,047
  -42,991
  -45,037
  -47,192
  -49,460
  -51,847
  -54,358
  -56,999

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  59
  60
  62
  63
  65
  67
  70
  72
  75
  78
  81
  84
  88
  91
  95
  99
  104
  109
  113
  119
  124
  130
  136
  143
  149
  157
  164
  172
  180
  189
Adjusted assets (=assets-cash), $m
  59
  60
  62
  63
  65
  67
  70
  72
  75
  78
  81
  84
  88
  91
  95
  99
  104
  109
  113
  119
  124
  130
  136
  143
  149
  157
  164
  172
  180
  189
Revenue / Adjusted assets
  0.542
  0.550
  0.548
  0.556
  0.554
  0.552
  0.543
  0.542
  0.547
  0.538
  0.543
  0.548
  0.545
  0.549
  0.547
  0.545
  0.548
  0.541
  0.549
  0.546
  0.548
  0.546
  0.544
  0.545
  0.544
  0.541
  0.543
  0.547
  0.544
  0.545
Average production assets, $m
  27
  28
  28
  29
  30
  31
  32
  33
  34
  36
  37
  39
  40
  42
  44
  46
  48
  50
  52
  54
  57
  60
  62
  65
  69
  72
  75
  79
  83
  87
Working capital, $m
  -17
  -17
  -18
  -18
  -19
  -19
  -20
  -21
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -30
  -31
  -32
  -34
  -35
  -37
  -39
  -41
  -43
  -45
  -47
  -49
  -51
  -54
Total debt, $m
  3
  4
  4
  5
  6
  7
  8
  9
  10
  11
  12
  13
  15
  16
  18
  19
  21
  23
  25
  27
  29
  31
  34
  36
  39
  42
  45
  48
  51
  54
Total liabilities, $m
  23
  24
  24
  25
  26
  27
  27
  28
  29
  31
  32
  33
  34
  36
  37
  39
  41
  43
  45
  47
  49
  51
  54
  56
  59
  62
  64
  68
  71
  74
Total equity, $m
  36
  37
  37
  38
  40
  41
  42
  44
  45
  47
  49
  51
  53
  55
  58
  60
  63
  66
  69
  72
  75
  79
  83
  87
  91
  95
  100
  104
  109
  115
Total liabilities and equity, $m
  59
  61
  61
  63
  66
  68
  69
  72
  74
  78
  81
  84
  87
  91
  95
  99
  104
  109
  114
  119
  124
  130
  137
  143
  150
  157
  164
  172
  180
  189
Debt-to-equity ratio
  0.090
  0.100
  0.120
  0.130
  0.150
  0.160
  0.180
  0.190
  0.210
  0.230
  0.240
  0.260
  0.270
  0.290
  0.300
  0.320
  0.330
  0.350
  0.360
  0.370
  0.380
  0.400
  0.410
  0.420
  0.430
  0.440
  0.450
  0.460
  0.470
  0.470
Adjusted equity ratio
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -17,725
  -18,133
  -18,599
  -19,122
  -19,702
  -20,338
  -21,030
  -21,780
  -22,588
  -23,455
  -24,380
  -25,369
  -26,423
  -27,543
  -28,731
  -29,990
  -31,323
  -32,732
  -34,222
  -35,794
  -37,453
  -39,203
  -41,047
  -42,991
  -45,037
  -47,192
  -49,460
  -51,847
  -54,358
  -56,999
Depreciation, amort., depletion, $m
  6
  6
  6
  6
  6
  6
  6
  6
  6
  7
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  8
  8
  8
  9
  9
  10
  10
  11
  11
Funds from operations, $m
  -17,720
  -18,127
  -18,593
  -19,116
  -19,696
  -20,332
  -21,024
  -21,774
  -22,581
  -23,448
  -24,375
  -25,364
  -26,418
  -27,537
  -28,725
  -29,984
  -31,317
  -32,726
  -34,215
  -35,787
  -37,446
  -39,195
  -41,039
  -42,982
  -45,029
  -47,183
  -49,451
  -51,837
  -54,348
  -56,988
Change in working capital, $m
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
Cash from operations, $m
  -17,719
  -18,127
  -18,593
  -19,116
  -19,695
  -20,331
  -21,024
  -21,773
  -22,581
  -23,447
  -24,374
  -25,364
  -26,417
  -27,536
  -28,724
  -29,983
  -31,315
  -32,725
  -34,213
  -35,786
  -37,444
  -39,194
  -41,038
  -42,980
  -45,027
  -47,181
  -49,449
  -51,835
  -54,345
  -56,986
Maintenance CAPEX, $m
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -8
  -8
  -8
  -9
  -9
  -10
  -10
  -11
New CAPEX, $m
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
Cash from investing activities, $m
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -5
  -5
  -5
  -6
  -7
  -7
  -7
  -7
  -8
  -8
  -8
  -8
  -9
  -10
  -10
  -11
  -11
  -11
  -12
  -12
  -14
  -14
  -15
Free cash flow, $m
  -17,724
  -18,131
  -18,597
  -19,120
  -19,700
  -20,336
  -21,029
  -21,778
  -22,586
  -23,453
  -24,380
  -25,370
  -26,423
  -27,543
  -28,731
  -29,990
  -31,323
  -32,733
  -34,222
  -35,795
  -37,454
  -39,204
  -41,048
  -42,991
  -45,038
  -47,193
  -49,461
  -51,848
  -54,359
  -57,000
Issuance/(repayment) of debt, $m
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
Issuance/(repurchase) of shares, $m
  17,726
  18,134
  18,600
  19,123
  19,703
  20,339
  21,032
  21,782
  22,589
  23,456
  24,382
  25,371
  26,425
  27,545
  28,733
  29,992
  31,325
  32,735
  34,225
  35,797
  37,457
  39,206
  41,051
  42,994
  45,041
  47,197
  49,465
  51,852
  54,363
  57,005
Cash from financing (excl. dividends), $m  
  17,727
  18,135
  18,601
  19,124
  19,704
  20,340
  21,033
  21,783
  22,590
  23,457
  24,383
  25,372
  26,426
  27,546
  28,735
  29,994
  31,327
  32,737
  34,227
  35,799
  37,459
  39,208
  41,053
  42,997
  45,044
  47,200
  49,468
  51,855
  54,366
  57,008
Total cash flow (excl. dividends), $m
  3
  3
  3
  4
  4
  4
  4
  4
  4
  5
  3
  3
  3
  3
  3
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
  6
  7
  7
  7
  8
Retained Cash Flow (-), $m
  -17,726
  -18,134
  -18,600
  -19,123
  -19,703
  -20,339
  -21,032
  -21,782
  -22,589
  -23,456
  -24,382
  -25,371
  -26,425
  -27,545
  -28,733
  -29,992
  -31,325
  -32,735
  -34,225
  -35,797
  -37,457
  -39,206
  -41,051
  -42,994
  -45,041
  -47,197
  -49,465
  -51,852
  -54,363
  -57,005
Prev. year cash balance distribution, $m
  47
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -17,676
  -18,130
  -18,596
  -19,120
  -19,699
  -20,335
  -21,028
  -21,777
  -22,585
  -23,452
  -24,379
  -25,369
  -26,422
  -27,542
  -28,730
  -29,989
  -31,322
  -32,731
  -34,220
  -35,793
  -37,452
  -39,201
  -41,046
  -42,989
  -45,035
  -47,190
  -49,458
  -51,845
  -54,356
  -56,997
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -16,947
  -16,598
  -16,184
  -15,743
  -15,269
  -14,758
  -14,206
  -13,611
  -12,974
  -12,295
  -11,577
  -10,826
  -10,046
  -9,246
  -8,435
  -7,621
  -6,815
  -6,028
  -5,269
  -4,548
  -3,874
  -3,253
  -2,690
  -2,190
  -1,752
  -1,377
  -1,062
  -802
  -593
  -429
Current shareholders' claim on cash, %
  1.9
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

FINANCIAL RATIOS  of  Arrowhead Pharmaceuticals (ARWR)

Valuation Ratios
P/E Ratio -28.6
Price to Sales 31.3
Price to Book 12
Price to Tangible Book
Price to Cash Flow -40.4
Price to Free Cash Flow -30.3
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 100%
Cap. Spend. - 3 Yr. Gr. Rate 32%
Financial Strength
Quick Ratio NaN
Current Ratio 0.1
LT Debt to Equity 3.7%
Total Debt to Equity 3.7%
Interest Coverage 0
Management Effectiveness
Return On Assets -29.3%
Ret/ On Assets - 3 Yr. Avg. -50.3%
Return On Total Capital -37.2%
Ret/ On T. Cap. - 3 Yr. Avg. -60.4%
Return On Equity -38.4%
Return On Equity - 3 Yr. Avg. -61.5%
Asset Turnover 0.3
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -93.5%
EBITDA Margin - 3 Yr. Avg. -31.2%
Operating Margin -119.4%
Oper. Margin - 3 Yr. Avg. -39.8%
Pre-Tax Margin -109.7%
Pre-Tax Margin - 3 Yr. Avg. -36.6%
Net Profit Margin -109.7%
Net Profit Margin - 3 Yr. Avg. -36.6%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

ARWR stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ARWR stock intrinsic value calculation we used $31.407709 million for the last fiscal year's total revenue generated by Arrowhead Pharmaceuticals. The default revenue input number comes from 0001 income statement of Arrowhead Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ARWR stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ARWR is calculated based on our internal credit rating of Arrowhead Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Arrowhead Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ARWR stock the variable cost ratio is equal to 55429%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for ARWR stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Arrowhead Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Arrowhead Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ARWR stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ARWR are equal to 84.2%.

Life of production assets of 7.8 years is the average useful life of capital assets used in Arrowhead Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ARWR is equal to -52.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $81.42235 million for Arrowhead Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 87.577 million for Arrowhead Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Arrowhead Pharmaceuticals at the current share price and the inputted number of shares is $1.1 billion.

RELATED COMPANIES Price Int.Val. Rating
ALNY Alnylam Pharma 69.37 4.39  str.sell
BNTC Benitec Biopha 2.41 0.52  str.sell
ABUS Arbutus Biopha 4.58 0.45  str.sell
DRNA Dicerna Pharma 13.58 0.48  str.sell

COMPANY NEWS

▶ Major Biotech Announcements Moving the Market   [Oct-10-18 10:30AM  ACCESSWIRE]
▶ ARWR Stock Sinks After Signing a Big Collaboration Deal   [Oct-09-18 10:45AM  InvestorPlace]
▶ Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip?   [Oct-08-18 08:01AM  Motley Fool]
▶ [$$] Honey, I Shrunk the Biotech Deal   [12:17PM  The Wall Street Journal]
▶ 3 Biotech Stocks That Soared This Week: Are They Buys?   [Sep-08-18 07:16AM  Motley Fool]
▶ Arrowhead Stock Is Not Done Rallying After Its 38% Jump   [Sep-07-18 02:10PM  InvestorPlace]
▶ Arrowhead Research: Fiscal 3Q Earnings Snapshot   [Aug-07-18 04:13PM  Associated Press]
▶ Why Arrowhead Pharmaceuticals, Inc. Stock Slumped Today   [Jul-30-18 12:36PM  Motley Fool]
▶ Harry Boxers three drug stocks to watch   [Jul-19-18 10:26AM  MarketWatch]
▶ The 4 Best Biotech Stocks of 2018 (So Far)   [Jul-14-18 07:16AM  Motley Fool]
▶ 3 Huge Biotech Winners in 2018 (So Far)   [Jul-11-18 09:15AM  Motley Fool]
▶ 4 Biotech Stocks That Tripled in the First Half of 2018   [Jul-02-18 03:06PM  Motley Fool]
▶ The 3 Best Biotech Stocks of 2018 So Far   [Jun-28-18 06:33AM  Motley Fool]
▶ 3 Soaring Biotech Stocks. Can They Keep Climbing?   [Jun-21-18 08:07AM  Motley Fool]
▶ 3 Biotech Stocks That Soared This Week: Are They Buys?   [May-12-18 07:17AM  Motley Fool]
▶ Four momentum stocks to watch amid earnings reports   [May-10-18 01:27PM  MarketWatch]
▶ Arrowhead Research: Fiscal 2Q Earnings Snapshot   [May-08-18 04:16PM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.